ClinicalTrials.gg
CompletedNCT05374525PILLARUpdated Dec 15, 2025Results posted

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

A Phase 4 interventional study of APRETUDE and Cabotegravir OLI in HIV Infections, sponsored by ViiV Healthcare. Completed at 17 sites in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
15th of 36
287 · median 200
Started
2022
with 2 others
Phase 4
3 of 36
1 open now
Registered
25th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 15th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 25th registered.

HIV Infections

4,736 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in the United States for men who have sex with men (MSM) and Transgender men ≥ 18 years of age. There are two types of participants in the study. Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available Cabotegravir PrEP via prescription from the PrEP provider at the corresponding site. Staff Study Participants (SSPs) will refer to site staff who are involved in administrative and clinical aspects of offering and administering PrEP to PSPs and will participate in the staff study assessments. PSPs who choose to opt for 1-month oral lead-in (OLI) will receive cabotegravir tablets for PrEP at Month 1 followed by APPRETUDE intramuscular (IM) injections on Month 2, 3 and every two months thereafter up to Month 13. PSPs who opt for Direct to injections (DTI) will receive APPRETUDE IM injections on Month 1, 2 and every two months thereafter up to Month 12. Month 6/7 refers to Month 6 (DTI)/ Month 7 (OLI). Month 12/13 refers to Month 12 (DTI)/ Month 13 (OLI).

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • Long-acting injectables
  • Implementation science
  • HIV
  • Pre-exposure prophylaxis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age inclusive, at the time of signing the .
  • No prior history of receiving CAB PrEP
  • negative test result at screening
  • Capable of giving signed informed consent form

Exclusion criteria

Exclusion Criteria:

  • indeterminate or positive test result during screening and prior to initiation of CAB PrEP
  • A participant of concurrent interventional clinical or implementation science study at any time during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    Dynamic Implementation (DI) - PSP

    Men who have sex with men (MSM) and transgender men (TGM) who were HIV negative as PSPs received APRETUDE injection (Direct to Injection - DTI) and had the choice to receive an optional cabotegravir tablets as oral lead in (OLI). PSPs had access to enhanced toolkits and digital health implementation supports.

    Drug: APRETUDE · Drug: Cabotegravir OLI

  • Experimental
    Routine Implementation (RI) - PSP

    MSM and transgender men who were HIV negative as PSPs received APRETUDE injection (DTI) and had the choice to use an optional cabotegravir tablets as OLI. PSPs had access to standard toolkits for APRETUDE to use as needed.

    Drug: APRETUDE · Drug: Cabotegravir OLI

Interventions

  • Available as intramuscular injection.

  • DrugCabotegravir OLI

    Available as marketed orally administered tablets.

06

What researchers measure

Primary outcomes

  1. Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs

    The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI)

    Time frame: At Month 12

Secondary outcomes

  1. Change From Baseline in FIM Score Assessed for SSPs

    This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

    Time frame: At Month 4 and Month 12 compared to baseline (Month 1)

  2. Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12

    Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  3. Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12

    Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  4. Mean FIM Score Assessed for PSPs

    The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  5. Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs

    The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  6. Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE

    The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  7. Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  8. Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Month 6 and Month 12

  9. Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Month 6 and Month 12

  10. Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Month 6 and Month 12

  11. Change From Baseline in AIM Score Assessed for PSPs

    This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.

    Time frame: At Month 6 and Month 12 compared to baseline (Month 1)

  12. Change From Baseline in FIM Score Assessed for PSPs

    This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline.

    Time frame: At Month 6 and Month 12 compared to baseline (Month 1)

  13. Percentage of PSPs With Change From Baseline in ISQ Responses

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months.

    Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)

  14. Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12

    Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  15. Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12

    Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  16. Mean FIM Score for Telehealth Delivery Assessed for SSPs

    The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  17. Mean AIM Score for Telehealth Delivery Assessed for SSPs

    The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  18. Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  19. Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 4 and Month 12

  20. Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 4 and Month 12

  21. Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs

    The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

    Time frame: At Month 4 and Month 12 compared to baseline (Month 1)

  22. Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs

    This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

    Time frame: At Month 4 and Month 12 compared to baseline (Month 1)

  23. Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.

    Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)

  24. Mean FIM Score for Telehealth Delivery Assessed for PSPs

    The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  25. Mean AIM Score for Telehealth Delivery Assessed for PSPs

    The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI)

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  26. Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  27. Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Month 6 and Month 12

  28. Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Month 6 and Month 12

  29. Number of PSPs With Response to the ISQs Recommending Telehealth Delivery

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Month 6 and Month 12

  30. Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs

    The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.

    Time frame: At Month 6 and Month 12 compared to baseline (Month 1)

  31. Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs

    The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.

    Time frame: At Month 6 and Month 12 compared to baseline (Month 1)

  32. Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.

    Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)

  33. Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery

    Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  34. Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery

    Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  35. Mean AIM Score Assessed for SSPs

    AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  36. Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  37. Change From Baseline in AIM Score Assessed for SSPs

    AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.

    Time frame: At Month 4 and Month 12 compared to baseline (Month 1)

  38. Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE

    The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item \[I\]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs). Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.

    Time frame: At Month 4 and 12 compared to Baseline (Month 1)

  39. Mean AIM Score Assessed for PSPs

    The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 6 and Month 12

  40. Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.

    Time frame: At Baseline (Month 1)

  41. Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI).

    Time frame: At Month 6

  42. Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: At Month 12

  43. Change From Baseline in Mean AIM Score in PSPs

    This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.

    Time frame: At Month 6 and Month 12 compared to baseline (Month 1)

  44. Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy

    In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV \& PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.

    Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)

  45. Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  46. Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  47. Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI

    Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  48. Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs)

    Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  49. Number of Injections Occurring Within Target Window From Target Date

    This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  50. Number of PSPs Completing Target Number of Injections

    Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  51. Number of PSPs With Perceptions of Facilitators to Fidelity to Injections

    Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  52. Number of PSPs With Perceptions of Barriers to Fidelity to Injections

    Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  53. Number of SSPs With Perceptions of Facilitators to Fidelity to Injections

    Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  54. Number of SSPs With Perceptions of Barriers to Fidelity to Injections

    Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  55. Number of SSPs Who Administer Sexual Health Assessment (SHA)

    In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  56. Number of Eligible PSPs for Which SHA Are Administered

    In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  57. Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  58. Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA

    In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  59. Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months

    In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question "Have you taken oral PreP in the last 6 months" and number of PSPs who had not heard of PreP.

    Time frame: Up to Month 12

  60. Number of PSPs Who Initiate APRETUDE After Taking the SHA

    In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP. Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  61. Number of PSPs With Perceptions of SHA

    Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  62. Number of SSPs With Perceptions of SHA

    In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  63. Number of Modifications Reported by SSPs Using FRAME-IS

    The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12

  64. Number of Modifications for Each Category Reported by SSPs Using FRAME-IS

    The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  65. Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS

    The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  66. Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies

    PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  67. Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE

    In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  68. Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs)

    Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  69. Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs

    The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  70. Number of PSPs Assessed for Perception of Facilitators

    General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  71. Number of PSPs Assessed for Perception of Barriers

    General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  72. Number of SSPs Assessed for Perception of Facilitators

    General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  73. Number of SSPs Assessed for Perception of Barriers

    General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

07

Results

Posted Dec 15, 2025

Participant flow

A total of 17 Clinics were randomized to Dynamic Implementation and Routine Implementation arms. In these clinics, a total of 201 patient study participants (PSPs) were enrolled in the study and all of them received study treatment and 86 Staff Study Participants (SSPs) were enrolled that included healthcare providers, nurses, staff performing injections, clinic administrators, pharmacists and laboratory staff.

Participant flow — Overall Study
MilestoneDynamic Implementation (DI)Routine Implementation (RI)
Started173114
Psp11784
Ssp5630
Completed13795
Not completed3619
Withdrew: Adverse event56
Withdrew: Lost to follow-up33
Withdrew: Physician decision22
Withdrew: Withdrawal by subject268

Outcome measures

PrimaryMean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs

The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI)

Time frame:
At Month 12
Reported as:
Mean · Scores on a scale
Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs4.37 ± 0.684.27 ± 0.68
SecondaryChange From Baseline in FIM Score Assessed for SSPs

This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

Time frame:
At Month 4 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in FIM Score Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
Month 4 compared to baseline (BL)-0.29 ± 0.920.08 ± 0.59
Month 12 compared to BL-0.01 ± 0.69-0.11 ± 0.86
SecondaryNumber of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12

Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12
ParticipantsDI - SSPRI - SSP
Clinic being flexible with scheduling (injection/ lab visits)51
Scheduling appointments in advance60
Training and consistent information provided to staff50
Increased communication for vulnerable populations31
Previous experience with CABENUVA/ APRETUDE22
SecondaryNumber of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12

Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12
ParticipantsDI - SSPRI - SSP
Staff burden to integrate the new process73
Complex team coordination42
Insurance challenges related to infrastructure42
Infrastructure Logistic challenges32
Follow-up with pharmacies needed to obtain APRETUDE22
SecondaryMean FIM Score Assessed for PSPs

The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Mean · Scores on a scale
Mean FIM Score Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Baseline4.33 ± 0.774.51 ± 0.70
Month 64.35 ± 0.754.46 ± 0.73
Month 124.36 ± 0.794.46 ± 0.72
SecondaryMean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs

The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Mean · Scores on a scale
Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Baseline4.46 ± 0.694.41 ± 0.68
Month 64.57 ± 0.644.57 ± 0.55
Month 124.61 ± 0.634.60 ± 0.67
SecondaryNumber of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE

The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
At Baseline - Overall, how are you feeling about taking APRETUDE? — Very Positive7964
At Baseline - Overall, how are you feeling about taking APRETUDE? — Somewhat Positive1910
At Baseline - Overall, how are you feeling about taking APRETUDE? — Neither positive nor negative71
At Baseline - Overall, how are you feeling about taking APRETUDE? — Somewhat negative00
At Baseline - Overall, how are you feeling about taking APRETUDE? — Very negative00
At Baseline - Overall, how are you feeling about taking APRETUDE? — Missing129
At Month 6 - Overall, how are you feeling about taking APRETUDE? — Very Positive7252
At Month 6 - Overall, how are you feeling about taking APRETUDE? — Somewhat Positive169
At Month 6 - Overall, how are you feeling about taking APRETUDE? — Neither positive nor negative21
At Month 6 - Overall, how are you feeling about taking APRETUDE? — Somewhat negative21
At Month 6 - Overall, how are you feeling about taking APRETUDE? — Very negative00
At Month 6 - Overall, how are you feeling about taking APRETUDE? — Missing2521
At Month 12 - Overall, how are you feeling about taking APRETUDE? — Very Positive6655
At Month 12 - Overall, how are you feeling about taking APRETUDE? — Somewhat Positive107
At Month 12 - Overall, how are you feeling about taking APRETUDE? — Neither positive nor negative01
At Month 12 - Overall, how are you feeling about taking APRETUDE? — Somewhat negative10
At Month 12 - Overall, how are you feeling about taking APRETUDE? — Very negative00
At Month 12 - Overall, how are you feeling about taking APRETUDE? — Missing4021
SecondaryNumber of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Very acceptable6055
At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Acceptable3119
At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Somewhat acceptable102
At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — A little acceptable40
At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Not at all acceptable00
At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Missing128
At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Very acceptable4940
At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Acceptable3116
At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Somewhat acceptable86
At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — A little acceptable30
At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Not at all acceptable11
At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Missing00
At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Very acceptable4139
At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Acceptable2118
At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Somewhat acceptable115
At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — A little acceptable31
At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Not at all acceptable00
At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Missing00
SecondaryNumber of PSPs With Responses to the ISQs Regarding Recommending APRETUDE

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Completely agree7249
At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Agree1812
At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Neither agree nor disagree20
At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Disagree01
At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Completely disagree01
At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Missing2521
At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Completely agree6452
At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Agree129
At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Neither agree nor disagree12
At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Disagree00
At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Completely disagree00
At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Missing4021
SecondaryNumber of PSPs With Responses to the ISQs Regarding Appointment Scheduling

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6- How easy or difficult is it to schedule appointments for your injections? — Very easy6046
Month 6- How easy or difficult is it to schedule appointments for your injections? — Somewhat easy2013
Month 6- How easy or difficult is it to schedule appointments for your injections? — Neither easy nor difficult53
Month 6- How easy or difficult is it to schedule appointments for your injections? — Somewhat difficult61
Month 6- How easy or difficult is it to schedule appointments for your injections? — Very difficult20
Month 6- How easy or difficult is it to schedule appointments for your injections? — I have not scheduled any appointments at the clinic/practice00
Month 6- How easy or difficult is it to schedule appointments for your injections? — Missing2421
Month 12- How easy or difficult is it to schedule appointments for your injections? — Very easy4946
Month 12- How easy or difficult is it to schedule appointments for your injections? — Somewhat easy1510
Month 12- How easy or difficult is it to schedule appointments for your injections? — Neither easy nor difficult64
Month 12- How easy or difficult is it to schedule appointments for your injections? — Somewhat difficult52
Month 12- How easy or difficult is it to schedule appointments for your injections? — Very difficult11
Month 12- How easy or difficult is it to schedule appointments for your injections? — I have not scheduled any appointments at the clinic/practice10
Month 12- How easy or difficult is it to schedule appointments for your injections? — Missing4021
SecondaryNumber of PSPs With Responses to the ISQs Regarding Appointment Rescheduling

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Very easy4425
Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Somewhat easy1417
Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Neither easy nor difficult14
Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Somewhat difficult62
Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Very difficult31
Month 6 - How easy or difficult is it to reschedule appointments for your injections? — I have not needed to reschedule any appointments2514
Month 12- How easy or difficult is it to reschedule appointments for your injections? — Very easy3930
Month 12- How easy or difficult is it to reschedule appointments for your injections? — Somewhat easy1317
Month 12- How easy or difficult is it to reschedule appointments for your injections? — Neither easy nor difficult44
Month 12- How easy or difficult is it to reschedule appointments for your injections? — Somewhat difficult86
Month 12- How easy or difficult is it to reschedule appointments for your injections? — Very difficult21
Month 12- How easy or difficult is it to reschedule appointments for your injections? — I have not needed to reschedule any appointments105
SecondaryChange From Baseline in AIM Score Assessed for PSPs

This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.

Time frame:
At Month 6 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in AIM Score Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 compared to BL0.17 ± 0.660.20 ± 0.72
Month 12 compared to BL0.27 ± 0.630.19 ± 0.87
SecondaryChange From Baseline in FIM Score Assessed for PSPs

This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline.

Time frame:
At Month 6 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in FIM Score Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 compared to BL0.01 ± 0.800.00 ± 0.89
Month 12 compared to BL0.01 ± 0.71-0.01 ± 0.92
SecondaryPercentage of PSPs With Change From Baseline in ISQ Responses

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months.

Time frame:
At Month 6 and Month 12 compared to Baseline (Month 1)
Reported as:
Number · Percentage of participants
Percentage of PSPs With Change From Baseline in ISQ Responses
Percentage of participantsDI- PSPRI- PSP
Change BL to M6 - How the participant felt about taking APRETUDE - Very positive3.0-2.8
Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat positive-0.71.0
Change BL to M6-How the participant felt about taking APRETUDE- Neither positive nor negative-4.50.3
Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat negative2.21.6
Change BL to M6 - How the participant felt about taking APRETUDE - Very negative0.00.0
Change BL to M12 - How the participant felt about taking APRETUDE-Very positive10.52.0
Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat positive-5.1-2.2
Change BL to M12-How the participant felt about taking APRETUDE-Neither positive nor negative-6.70.3
Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat negative1.30.0
Change BL to M12 - How the participant felt about taking APRETUDE-Very negative0.00.0
Change BL to M6 - Participant' acceptability for injection visits Q2M - Very acceptable-3.9-8.9
Change BL to M6 - Participant' acceptability for injection visits Q2M - Acceptable4.20.4
Change BL to M6 - Participant' acceptability for injection visits Q2M - Somewhat acceptable-0.86.9
Change BL to M6 - Participant' acceptability for injection visits Q2M - A little acceptable-0.50.0
Change BL to M6 - Participant' acceptability for injection visits Q2M - Not at all acceptable1.11.6
Change BL to M12 - Participant' acceptability for injection visits Q2M - Very acceptable-3.2-10.5
Change BL to M12 - Participant' acceptability for injection visits Q2M - Acceptable-1.93.6
Change BL to M12 - Participant' acceptability for injection visits Q2M - Somewhat acceptable4.95.3
Change BL to M12 - Participant' acceptability for injection visits Q2M - A little acceptable0.11.6
Change BL to M12 - Participant' acceptability for injection visits Q2M - Not at all acceptable0.00.0
SecondaryNumber of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12

Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
APRETUDE positive experience so far2320
Positive Experiences and General Satisfaction1412
Convenience and Ease of Use1511
Perceived effectiveness provides peace of mind72
Discomfort becoming more manageable15
APRETUDE met their expectations1518
Reduced anxiety about taking oral PrEP515
HIV protection107
APRETUDE more convenient than expected24
SecondaryNumber of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12

Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 1213
SecondaryMean FIM Score for Telehealth Delivery Assessed for SSPs

The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean FIM Score for Telehealth Delivery Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
Baseline4.01 ± 0.833.43 ± 1.23
Month 44.13 ± 0.904.08 ± 1.20
Month 124.26 ± 0.704.22 ± 1.30
SecondaryMean AIM Score for Telehealth Delivery Assessed for SSPs

The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean AIM Score for Telehealth Delivery Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
Baseline4.09 ± 0.823.26 ± 1.38
Month 44.16 ± 0.783.98 ± 1.16
Month 124.07 ± 0.784.17 ± 1.28
SecondaryNumber of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery
ParticipantsDI - SSPRI - SSP
Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — Yes5428
Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — No10
Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — I Don't Know12
Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — Yes2910
Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — No1514
Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — I Don't Know75
Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — Yes309
Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — No1112
Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — I Don't Know118
SecondaryNumber of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used
ParticipantsDI - SSPRI - SSP
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, at my clinic's service/system140
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, services/systems offered through PILLAR study10
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — No80
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — I don't know60
Month 4 - Video/virtual consultations for initial and follow-up visits — Yes, at my clinic's service/system230
Month 4 - Video/virtual consultations for initial and follow-up visits — Yes, services/systems offered through PILLAR study10
Month 4 - Video/virtual consultations for initial and follow-up visits — No10
Month 4 - Video/virtual consultations for initial and follow-up visits — I don't know40
Month 4 - Injection Administration: home health nurse to administer injection — Yes, at my clinic's service/system40
Month 4 - Injection Administration: home health nurse to administer injection — Yes, services/systems offered through PILLAR study30
Month 4 - Injection Administration: home health nurse to administer injection — No170
Month 4 - Injection Administration: home health nurse to administer injection — I don't know50
Month 4 - Injection appointment reminders: text/digital/email — Yes, at my clinic's service/system210
Month 4 - Injection appointment reminders: text/digital/email — Yes, services/systems offered through PILLAR study10
Month 4 - Injection appointment reminders: text/digital/email — No10
Month 4 - Injection appointment reminders: text/digital/email — I don't know60
Month 4 - HIV testing services: at home nurse testing — Yes, at my clinic's service/system80
Month 4 - HIV testing services: at home nurse testing — Yes, services/systems offered through PILLAR study30
Month 4 - HIV testing services: at home nurse testing — No140
Month 4 - HIV testing services: at home nurse testing — I don't know40
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, at my clinic's service/system215
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, services/systems offered through PILLAR study11
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — No53
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — I don't know30
Month 12 - Video/virtual consultations for initial and follow-up visits — Yes, at my clinic's service/system246
Month 12 - Video/virtual consultations for initial and follow-up visits — Yes, services/systems offered through PILLAR study21
Month 12 - Video/virtual consultations for initial and follow-up visits — No22
Month 12 - Video/virtual consultations for initial and follow-up visits — I don't know20
Month 12 - Injection Administration: home health nurse to administer injection — Yes, at my clinic's service/system61
Month 12 - Injection Administration: home health nurse to administer injection — Yes, services/systems offered through PILLAR study61
Month 12 - Injection Administration: home health nurse to administer injection — No167
Month 12 - Injection Administration: home health nurse to administer injection — I don't know20
Month 12 - Injection appointment reminders: text/digital/email — Yes, at my clinic's service/system235
Month 12 - Injection appointment reminders: text/digital/email — Yes, services/systems offered through PILLAR study11
Month 12 - Injection appointment reminders: text/digital/email — No23
Month 12 - Injection appointment reminders: text/digital/email — I don't know40
Month 12 - HIV testing services: at home nurse testing — Yes, at my clinic's service/system91
Month 12 - HIV testing services: at home nurse testing — Yes, services/systems offered through PILLAR study61
Month 12 - HIV testing services: at home nurse testing — No137
Month 12 - HIV testing services: at home nurse testing — I don't know20
SecondaryNumber of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used
ParticipantsDI - SSPRI - SSP
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Very helpful100
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Helpful30
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Somewhat helpful10
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — A little helpful00
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Not at all helpful00
Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — I have not personally used this10
Month 4 - Video/virtual consultations for initial and follow-up visits — Very helpful140
Month 4 - Video/virtual consultations for initial and follow-up visits — Helpful50
Month 4 - Video/virtual consultations for initial and follow-up visits — Somewhat helpful20
Month 4 - Video/virtual consultations for initial and follow-up visits — A little helpful00
Month 4 - Video/virtual consultations for initial and follow-up visits — Not at all helpful00
Month 4 - Video/virtual consultations for initial and follow-up visits — I have not personally used this30
Month 4 - Injection Administration: home health nurse to administer injection — Very helpful20
Month 4 - Injection Administration: home health nurse to administer injection — Helpful20
Month 4 - Injection Administration: home health nurse to administer injection — Somewhat helpful10
Month 4 - Injection Administration: home health nurse to administer injection — A little helpful00
Month 4 - Injection Administration: home health nurse to administer injection — Not at all helpful00
Month 4 - Injection Administration: home health nurse to administer injection — I have not personally used this20
Month 4 - Injection appointment reminders: text/digital/email — Very helpful140
Month 4 - Injection appointment reminders: text/digital/email — Helpful30
Month 4 - Injection appointment reminders: text/digital/email — Somewhat helpful10
Month 4 - Injection appointment reminders: text/digital/email — A little helpful00
Month 4 - Injection appointment reminders: text/digital/email — Not at all helpful10
Month 4 - Injection appointment reminders: text/digital/email — I have not personally used this30
Month 4 - HIV testing services: at home nurse testing — Very helpful30
Month 4 - HIV testing services: at home nurse testing — Helpful20
Month 4 - HIV testing services: at home nurse testing — Somewhat helpful10
Month 4 - HIV testing services: at home nurse testing — A little helpful00
Month 4 - HIV testing services: at home nurse testing — Not at all helpful10
Month 4 - HIV testing services: at home nurse testing — I have not personally used this40
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Very helpful94
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Helpful72
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Somewhat helpful40
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — A little helpful00
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Not at all helpful00
Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — I have not personally used this20
Month 12 - Video/virtual consultations for initial and follow-up visits — Very helpful134
Month 12 - Video/virtual consultations for initial and follow-up visits — Helpful61
Month 12 - Video/virtual consultations for initial and follow-up visits — Somewhat helpful32
Month 12 - Video/virtual consultations for initial and follow-up visits — A little helpful00
Month 12 - Video/virtual consultations for initial and follow-up visits — Not at all helpful00
Month 12 - Video/virtual consultations for initial and follow-up visits — I have not personally used this40
Month 12 - Injection Administration: home health nurse to administer injection — Very helpful51
Month 12 - Injection Administration: home health nurse to administer injection — Helpful20
Month 12 - Injection Administration: home health nurse to administer injection — Somewhat helpful10
Month 12 - Injection Administration: home health nurse to administer injection — A little helpful00
Month 12 - Injection Administration: home health nurse to administer injection — Not at all helpful00
Month 12 - Injection Administration: home health nurse to administer injection — I have not personally used this41
Month 12 - Injection appointment reminders: text/digital/email — Very helpful164
Month 12 - Injection appointment reminders: text/digital/email — Helpful42
Month 12 - Injection appointment reminders: text/digital/email — Somewhat helpful10
Month 12 - Injection appointment reminders: text/digital/email — A little helpful10
Month 12 - Injection appointment reminders: text/digital/email — Not at all helpful00
Month 12 - Injection appointment reminders: text/digital/email — I have not personally used this20
Month 12 - HIV testing services: at home nurse testing — Very helpful91
Month 12 - HIV testing services: at home nurse testing — Helpful10
Month 12 - HIV testing services: at home nurse testing — Somewhat helpful10
Month 12 - HIV testing services: at home nurse testing — A little helpful00
Month 12 - HIV testing services: at home nurse testing — Not at all helpful00
Month 12 - HIV testing services: at home nurse testing — I have not personally used this41
SecondaryChange From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs

The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

Time frame:
At Month 4 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
Month 4 compared to BL-0.11 ± 1.210.20 ± 1.21
Month 12 compared to BL-0.06 ± 1.030.16 ± 0.64
SecondaryChange From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs

This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

Time frame:
At Month 4 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
Month 4 compared to BL-0.13 ± 0.920.53 ± 1.21
Month 12 compared to BL-0.38 ± 0.970.41 ± 1.02
SecondaryPercentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.

Time frame:
At Month 4 and Month 12 compared to Baseline (Month 1)
Reported as:
Number · Percentage of participants
Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery
Percentage of participantsDI- SSPRI- SSP
Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES-39.6-58.9
Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO27.648.3
Change BL to M4-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW11.910.6
Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES-38.7-62.3
Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO19.441.4
Change BL to M12-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW19.420.9
SecondaryMean FIM Score for Telehealth Delivery Assessed for PSPs

The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Mean · Scores on a scale
Mean FIM Score for Telehealth Delivery Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Baseline4.40 ± 0.724.15 ± 0.97
Month 64.56 ± 0.564.19 ± 0.76
Month 124.25 ± 0.894.38 ± 0.70
SecondaryMean AIM Score for Telehealth Delivery Assessed for PSPs

The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI)

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Mean · Scores on a scale
Mean AIM Score for Telehealth Delivery Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Baseline4.32 ± 0.764.13 ± 0.91
Month 64.56 ± 0.574.25 ± 0.70
Month 124.21 ± 0.934.27 ± 0.67
SecondaryNumber of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Baseline- Have you used any of the telehealth care options that your clinic offers? — Yes7248
Baseline- Have you used any of the telehealth care options that your clinic offers? — No1410
Baseline- Have you used any of the telehealth care options that your clinic offers? — I don't know00
Baseline- Have you used any of the telehealth care options that your clinic offers? — Missing00
Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — Yes4124
Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — No4934
Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — I don't know47
Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — Missing2319
Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Yes179
Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — No2214
Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — I don't know11
Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Missing10
Month 6- TEL services received: Nurse coming home to give an HIV test — Yes32
Month 6- TEL services received: Nurse coming home to give an HIV test — No3621
Month 6- TEL services received: Nurse coming home to give an HIV test — I don't know11
Month 6- TEL services received: Nurse coming home to give an HIV test — Missing10
Month 6- TEL services received: Receiving reminders about scheduled injection appointment — Yes3622
Month 6- TEL services received: Receiving reminders about scheduled injection appointment — No41
Month 6- TEL services received: Receiving reminders about scheduled injection appointment — I don't know01
Month 6- TEL services received: Receiving reminders about scheduled injection appointment — Missing10
Month 6- TEL services received: Scheduling injection appointment online — Yes2415
Month 6- TEL services received: Scheduling injection appointment online — No158
Month 6- TEL services received: Scheduling injection appointment online — I don't know11
Month 6- TEL services received: Scheduling injection appointment online — Missing10
Month 6- TEL services received: Nurse coming home to give the injection — Yes22
Month 6- TEL services received: Nurse coming home to give the injection — No3821
Month 6- TEL services received: Nurse coming home to give the injection — I don't know01
Month 6- TEL services received: Nurse coming home to give the injection — Missing10
Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — Yes2925
Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — No4738
Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — I don't know10
Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — Missing4021
Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Yes1110
Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — No1713
Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — I don't know12
Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Missing00
Month 12- TEL services received: Nurse coming home to give an HIV test — Yes32
Month 12- TEL services received: Nurse coming home to give an HIV test — No2623
Month 12- TEL services received: Nurse coming home to give an HIV test — I don't know00
Month 12- TEL services received: Nurse coming home to give an HIV test — Missing00
Month 12- TEL services received: Receiving reminders about scheduled injection appointment — Yes2825
Month 12- TEL services received: Receiving reminders about scheduled injection appointment — No10
Month 12- TEL services received: Receiving reminders about scheduled injection appointment — I don't know00
Month 12- TEL services received: Receiving reminders about scheduled injection appointment — Missing00
Month 12- TEL services received: Scheduling injection appointment online — Yes1613
Month 12- TEL services received: Scheduling injection appointment online — No1312
Month 12- TEL services received: Scheduling injection appointment online — I don't know00
Month 12- TEL services received: Scheduling injection appointment online — Missing00
Month 12- TEL services received: Nurse coming home to give the injection — Yes32
Month 12- TEL services received: Nurse coming home to give the injection — No2523
Month 12- TEL services received: Nurse coming home to give the injection — I don't know10
Month 12- TEL services received: Nurse coming home to give the injection — Missing00
SecondaryNumber of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6- Doctor ordering HIV test at a lab near home to take the test — Very comfortable128
Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat comfortable41
Month 6- Doctor ordering HIV test at a lab near home to take the test — Neither comfortable nor uncomfortable10
Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat uncomfortable00
Month 6- Doctor ordering HIV test at a lab near home to take the test — Not comfortable at all00
Month 6- A nurse coming home to give an HIV test — Very comfortable21
Month 6- A nurse coming home to give an HIV test — Somewhat comfortable01
Month 6- A nurse coming home to give an HIV test — Neither comfortable nor uncomfortable10
Month 6- A nurse coming home to give an HIV test — Somewhat uncomfortable00
Month 6- A nurse coming home to give an HIV test — Not comfortable at all00
Month 6- Receiving reminders about scheduled injection appointment — Very comfortable3320
Month 6- Receiving reminders about scheduled injection appointment — Somewhat comfortable32
Month 6- Receiving reminders about scheduled injection appointment — Neither comfortable nor uncomfortable00
Month 6- Receiving reminders about scheduled injection appointment — Somewhat uncomfortable00
Month 6- Receiving reminders about scheduled injection appointment — Not comfortable at all00
Month 6- Scheduling injection appointment online — Very comfortable2013
Month 6- Scheduling injection appointment online — Somewhat comfortable31
Month 6- Scheduling injection appointment online — Neither comfortable nor uncomfortable01
Month 6- Scheduling injection appointment online — Somewhat uncomfortable10
Month 6- Scheduling injection appointment online — Not comfortable at all00
Month 6- A nurse coming home to give the injection — Very comfortable21
Month 6- A nurse coming home to give the injection — Somewhat comfortable00
Month 6- A nurse coming home to give the injection — Neither comfortable nor uncomfortable00
Month 6- A nurse coming home to give the injection — Somewhat uncomfortable01
Month 6- A nurse coming home to give the injection — Not comfortable at all00
Month 12- Doctor ordering HIV test at a lab near home to take the test — Very comfortable118
Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat comfortable00
Month 12- Doctor ordering HIV test at a lab near home to take the test — Neither comfortable nor uncomfortable02
Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat uncomfortable00
Month 12- Doctor ordering HIV test at a lab near home to take the test — Not comfortable at all00
Month 12- A nurse coming to home to give an HIV test — Very comfortable22
Month 12- A nurse coming to home to give an HIV test — Somewhat comfortable10
Month 12- A nurse coming to home to give an HIV test — Neither comfortable nor uncomfortable00
Month 12- A nurse coming to home to give an HIV test — Somewhat uncomfortable00
Month 12- A nurse coming to home to give an HIV test — Not comfortable at all00
Month 12- Receiving reminders about scheduled injection appointment — Very comfortable2621
Month 12- Receiving reminders about scheduled injection appointment — Somewhat comfortable22
Month 12- Receiving reminders about scheduled injection appointment — Neither comfortable nor uncomfortable01
Month 12- Receiving reminders about scheduled injection appointment — Somewhat uncomfortable01
Month 12- Receiving reminders about scheduled injection appointment — Not comfortable at all00
Month 12- Scheduling injection appointment online — Very comfortable1511
Month 12- Scheduling injection appointment online — Somewhat comfortable11
Month 12- Scheduling injection appointment online — Neither comfortable nor uncomfortable01
Month 12- Scheduling injection appointment online — Somewhat uncomfortable00
Month 12- Scheduling injection appointment online — Not comfortable at all00
Month 12- A nurse coming home to give the injection — Very comfortable32
Month 12- A nurse coming home to give the injection — Somewhat comfortable00
Month 12- A nurse coming home to give the injection — Neither comfortable nor uncomfortable00
Month 12- A nurse coming home to give the injection — Somewhat uncomfortable00
Month 12- A nurse coming home to give the injection — Not comfortable at all00
SecondaryNumber of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6- Doctor ordering HIV test at a lab near home to take the test — Very convenient128
Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat convenient30
Month 6- Doctor ordering HIV test at a lab near home to take the test — Neither convenient nor inconvenient21
Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat inconvenient00
Month 6- Doctor ordering HIV test at a lab near home to take the test — Very inconvenient00
Month 6- A nurse coming home to give an HIV test — Very convenient12
Month 6- A nurse coming home to give an HIV test — Somewhat convenient10
Month 6- A nurse coming home to give an HIV test — Neither convenient nor inconvenient10
Month 6- A nurse coming home to give an HIV test — Somewhat inconvenient00
Month 6- A nurse coming home to give an HIV test — Very inconvenient00
Month 6- Receiving reminders about scheduled injection appointment — Very convenient3118
Month 6- Receiving reminders about scheduled injection appointment — Somewhat convenient44
Month 6- Receiving reminders about scheduled injection appointment — Neither convenient nor inconvenient10
Month 6- Receiving reminders about scheduled injection appointment — Somewhat inconvenient00
Month 6- Receiving reminders about scheduled injection appointment — Very inconvenient00
Month 6- Scheduling your injection appointment online — Very convenient1913
Month 6- Scheduling your injection appointment online — Somewhat convenient31
Month 6- Scheduling your injection appointment online — Neither convenient nor inconvenient20
Month 6- Scheduling your injection appointment online — Somewhat inconvenient01
Month 6- Scheduling your injection appointment online — Very inconvenient00
Month 6- A nurse coming home to give the injection — Very convenient21
Month 6- A nurse coming home to give the injection — Somewhat convenient00
Month 6- A nurse coming home to give the injection — Neither convenient nor inconvenient00
Month 6- A nurse coming home to give the injection — Somewhat inconvenient00
Month 6- A nurse coming home to give the injection — Very inconvenient01
Month 12- Doctor ordering HIV test at a lab near home to take the test — Very convenient119
Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat convenient00
Month 12- Doctor ordering HIV test at a lab near home to take the test — Neither convenient nor inconvenient01
Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat inconvenient00
Month 12- Doctor ordering HIV test at a lab near home to take the test — Very inconvenient00
Month 12- A nurse coming home to give an HIV test — Very convenient22
Month 12- A nurse coming home to give an HIV test — Somewhat convenient10
Month 12- A nurse coming home to give an HIV test — Neither convenient nor inconvenient00
Month 12- A nurse coming home to give an HIV test — Somewhat inconvenient00
Month 12- A nurse coming home to give an HIV test — Very inconvenient00
Month 12- Receiving reminders about scheduled injection appointment — Very convenient2822
Month 12- Receiving reminders about scheduled injection appointment — Somewhat convenient02
Month 12- Receiving reminders about scheduled injection appointment — Neither convenient nor inconvenient01
Month 12- Receiving reminders about scheduled injection appointment — Somewhat inconvenient00
Month 12- Receiving reminders about scheduled injection appointment — Very inconvenient00
Month 12- Scheduling your injection appointment online — Very convenient1411
Month 12- Scheduling your injection appointment online — Somewhat convenient11
Month 12- Scheduling your injection appointment online — Neither convenient nor inconvenient11
Month 12- Scheduling your injection appointment online — Somewhat inconvenient00
Month 12- Scheduling your injection appointment online — Very inconvenient00
Month 12- A nurse coming home to give the injection — Very convenient32
Month 12- A nurse coming home to give the injection — Somewhat convenient00
Month 12- A nurse coming home to give the injection — Neither convenient nor inconvenient00
Month 12- A nurse coming home to give the injection — Somewhat inconvenient00
Month 12- A nurse coming home to give the injection — Very inconvenient00
SecondaryNumber of PSPs With Response to the ISQs Recommending Telehealth Delivery

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Month 6 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Response to the ISQs Recommending Telehealth Delivery
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 - I would recommend telehealth services for APRETUDE to other people. — Completely agree2912
Month 6 - I would recommend telehealth services for APRETUDE to other people. — Agree99
Month 6 - I would recommend telehealth services for APRETUDE to other people. — Neither agree not disagree13
Month 6 - I would recommend telehealth services for APRETUDE to other people. — Disagree10
Month 6 - I would recommend telehealth services for APRETUDE to other people. — Completely disagree00
Month 6 - I would recommend telehealth services for APRETUDE to other people. — Missing10
Month 12 - I would recommend telehealth services for APRETUDE to other people. — Completely agree2020
Month 12 - I would recommend telehealth services for APRETUDE to other people. — Agree72
Month 12 - I would recommend telehealth services for APRETUDE to other people. — Neither agree not disagree23
Month 12 - I would recommend telehealth services for APRETUDE to other people. — Disagree00
Month 12 - I would recommend telehealth services for APRETUDE to other people. — Completely disagree00
Month 12 - I would recommend telehealth services for APRETUDE to other people. — Missing00
SecondaryChange From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs

The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.

Time frame:
At Month 6 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 compared to BL0.08 ± 0.650.25 ± 1.23
Month 12 compared to BL-0.35 ± 0.780.17 ± 1.21
SecondaryChange From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs

The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.

Time frame:
At Month 6 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 compared to BL0.09 ± 0.640.26 ± 1.26
Month 12 compared to BL-0.39 ± 0.920.21 ± 1.11
SecondaryPercentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.

Time frame:
At Month 6 and Month 12 compared to Baseline (Month 1)
Reported as:
Number · Percentage of participants
Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery
Percentage of participantsDI- PSPRI- PSP
Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - YES-40.1-45.8
Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - NO35.835.1
Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW4.310.8
Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - YES-46.1-43.1
Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - NO44.843.1
Change BL to M12-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW1.30.0
SecondaryNumber of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery

Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery
ParticipantsDI - SSPRI - SSP
Video consultation — Very easy124
Video consultation — Somewhat easy32
Video consultation — Neither easy nor difficult61
Video consultation — Somewhat Difficult00
Video consultation — Very Difficult00
Video consultation — I don't use this system61
Telephone consultation — Very easy142
Telephone consultation — Somewhat easy42
Telephone consultation — Neither easy nor difficult30
Telephone consultation — Somewhat Difficult10
Telephone consultation — Very Difficult00
Telephone consultation — I don't use this system30
Remote monitoring of patients — Very easy31
Remote monitoring of patients — Somewhat easy50
Remote monitoring of patients — Neither easy nor difficult21
Remote monitoring of patients — Somewhat Difficult00
Remote monitoring of patients — Very Difficult00
Remote monitoring of patients — I don't use this system11
Online appointment scheduling — Very easy33
Online appointment scheduling — Somewhat easy20
Online appointment scheduling — Neither easy nor difficult30
Online appointment scheduling — Somewhat Difficult00
Online appointment scheduling — Very Difficult00
Online appointment scheduling — I don't use this system20
Patient portal conversations: ability for patients to send messages to providers — Very easy137
Patient portal conversations: ability for patients to send messages to providers — Somewhat easy40
Patient portal conversations: ability for patients to send messages to providers — Neither easy nor difficult40
Patient portal conversations: ability for patients to send messages to providers — Somewhat Difficult01
Patient portal conversations: ability for patients to send messages to providers — Very Difficult00
Patient portal conversations: ability for patients to send messages to providers — I don't use this system20
At-home testing services — Very easy41
At-home testing services — Somewhat easy11
At-home testing services — Neither easy nor difficult20
At-home testing services — Somewhat Difficult00
At-home testing services — Very Difficult00
At-home testing services — I don't use this system30
Send and receiving patient reported outcomes questionnaires via an online system — Very easy31
Send and receiving patient reported outcomes questionnaires via an online system — Somewhat easy41
Send and receiving patient reported outcomes questionnaires via an online system — Neither easy nor difficult30
Send and receiving patient reported outcomes questionnaires via an online system — Somewhat Difficult00
Send and receiving patient reported outcomes questionnaires via an online system — Very Difficult00
Send and receiving patient reported outcomes questionnaires via an online system — I don't use this system20
Online prescription refills — Very easy146
Online prescription refills — Somewhat easy30
Online prescription refills — Neither easy nor difficult40
Online prescription refills — Somewhat Difficult00
Online prescription refills — Very Difficult00
Online prescription refills — I don't use this system20
Online portal for patients to access medical documents, such as visit summaries and test results — Very easy126
Online portal for patients to access medical documents, such as visit summaries and test results — Somewhat easy60
Online portal for patients to access medical documents, such as visit summaries and test results — Neither easy nor difficult40
Online portal for patients to access medical documents, such as visit summaries and test results — Somewhat Difficult00
Online portal for patients to access medical documents, such as visit summaries and test results — Very Difficult00
Online portal for patients to access medical documents, such as visit summaries and test results — I don't use this system20
Text messaging with patients about care — Very easy74
Text messaging with patients about care — Somewhat easy31
Text messaging with patients about care — Neither easy nor difficult21
Text messaging with patients about care — Somewhat Difficult00
Text messaging with patients about care — Very Difficult00
Text messaging with patients about care — I don't use this system10
Email reminders to patient about upcoming visits — Very easy103
Email reminders to patient about upcoming visits — Somewhat easy41
Email reminders to patient about upcoming visits — Neither easy nor difficult20
Email reminders to patient about upcoming visits — Somewhat Difficult00
Email reminders to patient about upcoming visits — Very Difficult00
Email reminders to patient about upcoming visits — I don't use this system30
Text reminders — Very easy126
Text reminders — Somewhat easy51
Text reminders — Neither easy nor difficult21
Text reminders — Somewhat Difficult00
Text reminders — Very Difficult00
Text reminders — I don't use this system30
Automated phone call reminders — Very easy94
Automated phone call reminders — Somewhat easy41
Automated phone call reminders — Neither easy nor difficult40
Automated phone call reminders — Somewhat Difficult00
Automated phone call reminders — Very Difficult00
Automated phone call reminders — I don't use this system20
Staff phone call reminder — Very easy97
Staff phone call reminder — Somewhat easy61
Staff phone call reminder — Neither easy nor difficult10
Staff phone call reminder — Somewhat Difficult00
Staff phone call reminder — Very Difficult00
Staff phone call reminder — I don't use this system20
Sending motivational reminders to help patients persist on APRETUDE — Very easy21
Sending motivational reminders to help patients persist on APRETUDE — Somewhat easy00
Sending motivational reminders to help patients persist on APRETUDE — Neither easy nor difficult00
Sending motivational reminders to help patients persist on APRETUDE — Somewhat Difficult00
Sending motivational reminders to help patients persist on APRETUDE — Very Difficult00
Sending motivational reminders to help patients persist on APRETUDE — I don't use this system00
Sending cabotegravir oral lead in to patient's home — Very easy41
Sending cabotegravir oral lead in to patient's home — Somewhat easy10
Sending cabotegravir oral lead in to patient's home — Neither easy nor difficult11
Sending cabotegravir oral lead in to patient's home — Somewhat Difficult00
Sending cabotegravir oral lead in to patient's home — Very Difficult00
Sending cabotegravir oral lead in to patient's home — I don't use this system10
Insurance/benefits verification — Very easy105
Insurance/benefits verification — Somewhat easy71
Insurance/benefits verification — Neither easy nor difficult31
Insurance/benefits verification — Somewhat Difficult10
Insurance/benefits verification — Very Difficult10
Insurance/benefits verification — I don't use this system20
SecondaryNumber of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery

Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Telehealth Used for any service25
Telehealth Used for APRETUDE15
Telehealth used for things OTHER than APRETUDE, only10
Telehealth Not Used212
Not Asked About Telehealth184
Telehealth used/not used- Missing10
Telehealth DI Used50
Teleconsultant Used10
Online Appointment Scheduler Used00
Reminders Used30
Home tests Used00
Local labs Used00
Online portal Used00
Home health nurses Used00
Screenings and assessments Used10
SecondaryMean AIM Score Assessed for SSPs

AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean AIM Score Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
AIM-INT (Baseline)4.69 ± 0.434.66 ± 0.48
AIM-INT (Month 4)4.33 ± 0.684.43 ± 0.56
AIM-INT (Month 12)4.41 ± 0.574.52 ± 0.56
AIM-IMP (Baseline)3.97 ± 0.834.05 ± 0.76
AIM-IMP (Month 4)3.92 ± 0.803.86 ± 0.84
AIM-IMP (Month 12)4.09 ± 0.673.90 ± 1.08
SecondaryNumber of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE
ParticipantsDI - SSPRI - SSP
Baseline- Management of scheduling injection appointments during correct injection windows — Extremely concerned32
Baseline- Management of scheduling injection appointments during correct injection windows — Moderately concerned54
Baseline- Management of scheduling injection appointments during correct injection windows — Somewhat concerned132
Baseline- Management of scheduling injection appointments during correct injection windows — Slightly concerned57
Baseline- Management of scheduling injection appointments during correct injection windows — Not at all concerned3015
Baseline- Management of rescheduling appointments during correct injection windows — Extremely concerned42
Baseline- Management of rescheduling appointments during correct injection windows — Moderately concerned46
Baseline- Management of rescheduling appointments during correct injection windows — Somewhat concerned153
Baseline- Management of rescheduling appointments during correct injection windows — Slightly concerned69
Baseline- Management of rescheduling appointments during correct injection windows — Not at all concerned2710
Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Extremely concerned43
Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Moderately concerned54
Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Somewhat concerned165
Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Slightly concerned49
Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Not at all concerned279
Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Extremely concerned55
Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Moderately concerned55
Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Somewhat concerned154
Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Slightly concerned54
Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Not at all concerned2612
Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Extremely concerned53
Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Moderately concerned44
Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Somewhat concerned114
Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Slightly concerned95
Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Not at all concerned2714
Month 4- Management of scheduling injection appointments during correct injection windows — Extremely concerned22
Month 4- Management of scheduling injection appointments during correct injection windows — Moderately concerned50
Month 4- Management of scheduling injection appointments during correct injection windows — Somewhat concerned62
Month 4- Management of scheduling injection appointments during correct injection windows — Slightly concerned34
Month 4- Management of scheduling injection appointments during correct injection windows — Not at all concerned3521
Month 4- Management of rescheduling appointments during correct injection windows — Extremely concerned22
Month 4- Management of rescheduling appointments during correct injection windows — Moderately concerned51
Month 4- Management of rescheduling appointments during correct injection windows — Somewhat concerned82
Month 4- Management of rescheduling appointments during correct injection windows — Slightly concerned49
Month 4- Management of rescheduling appointments during correct injection windows — Not at all concerned3215
Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Extremely concerned12
Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Moderately concerned51
Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Somewhat concerned111
Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Slightly concerned710
Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Not at all concerned2715
Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Extremely concerned32
Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Moderately concerned72
Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Somewhat concerned102
Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Slightly concerned67
Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Not at all concerned2516
Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Extremely concerned13
Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Moderately concerned52
Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Somewhat concerned151
Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Slightly concerned53
Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Not at all concerned2520
Month 12- Management of scheduling injection appointments every 2 months during injection windows — Extremely concerned01
Month 12- Management of scheduling injection appointments every 2 months during injection windows — Moderately concerned42
Month 12- Management of scheduling injection appointments every 2 months during injection windows — Somewhat concerned52
Month 12- Management of scheduling injection appointments every 2 months during injection windows — Slightly concerned74
Month 12- Management of scheduling injection appointments every 2 months during injection windows — Not at all concerned3620
Month 12- Management of rescheduling appointments during correct injection windows — Extremely concerned11
Month 12- Management of rescheduling appointments during correct injection windows — Moderately concerned43
Month 12- Management of rescheduling appointments during correct injection windows — Somewhat concerned81
Month 12- Management of rescheduling appointments during correct injection windows — Slightly concerned107
Month 12- Management of rescheduling appointments during correct injection windows — Not at all concerned2917
Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Extremely concerned21
Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Moderately concerned32
Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Somewhat concerned83
Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Slightly concerned119
Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Not at all concerned2814
Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Extremely concerned43
Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Moderately concerned40
Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Somewhat concerned85
Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Slightly concerned109
Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Not at all concerned2612
Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Extremely concerned11
Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Moderately concerned33
Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Somewhat concerned102
Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Slightly concerned96
Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Not at all concerned2917
SecondaryChange From Baseline in AIM Score Assessed for SSPs

AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.

Time frame:
At Month 4 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in AIM Score Assessed for SSPs
Scores on a scaleDI - SSPRI - SSP
AIM-INT, Month 4 compared to BL-0.36 ± 0.66-0.22 ± 0.67
AIM-INT, Month 12 compared to BL-0.33 ± 0.50-0.11 ± 0.74
AIM-IMP, Month 4 compared to BL-0.06 ± 0.77-0.16 ± 0.81
AIM-IMP, Month 12 compared to BL0.04 ± 0.84-0.20 ± 1.24
SecondaryPercentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item \[I\]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs). Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.

Time frame:
At Month 4 and 12 compared to Baseline (Month 1)
Reported as:
Number · Percentage of participants
Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE
Percentage of participantsDI - SSPRI - SSP
Change BL to M4 - I1: Extremely concerned-1.40.2
Change BL to M4 - I1: Moderately concerned0.9-13.3
Change BL to M4 - I1: Somewhat concerned-11.40.2
Change BL to M4 - I1: Slightly concerned-3.0-9.5
Change BL to M4 - I1: Not at all concerned15.122.4
Change BL to M4 - I2: Extremely concerned-3.20.2
Change BL to M4 - I2: Moderately concerned2.7-16.6
Change BL to M4 - I2: Somewhat concerned-11.1-3.1
Change BL to M4 - I2: Slightly concerned-2.91.0
Change BL to M4 - I2: Not at all concerned14.518.4
Change BL to M4 - I3: Extremely concerned-5.2-3.1
Change BL to M4 - I3: Moderately concerned0.9-9.9
Change BL to M4 - I3: Somewhat concerned-7.0-13.2
Change BL to M4 - I3: Slightly concerned6.64.5
Change BL to M4 - I3: Not at all concerned4.721.7
Change BL to M4 - I4: Extremely concerned-3.0-9.8
Change BL to M4 - I4: Moderately concerned4.8-9.8
Change BL to M4 - I4: Somewhat concerned-7.2-6.4
Change BL to M4 - I4: Slightly concerned2.810.8
Change BL to M4 - I4: Not at all concerned2.615.2
Change BL to M4 - I5: Extremely concerned-7.00.3
Change BL to M4 - I5: Moderately concerned2.7-6.4
Change BL to M4 - I5: Somewhat concerned9.8-9.9
Change BL to M4 - I5: Slightly concerned-6.3-6.3
Change BL to M4 - I5: Not at all concerned0.822.3
Change BL to M12 - I1: Extremely concerned-5.4-3.2
Change BL to M12 - I1: Moderately concerned-1.2-6.4
Change BL to M12 - I1: Somewhat concerned-13.60.2
Change BL to M12 - I1: Slightly concerned4.5-9.5
Change BL to M12 - I1: Not at all concerned15.719.0
Change BL to M12 - I2: Extremely concerned-5.2-3.2
Change BL to M12 - I2: Moderately concerned0.5-9.7
Change BL to M12 - I2: Somewhat concerned-11.4-6.6
Change BL to M12 - I2: Slightly concerned8.5-5.9
Change BL to M12 - I2: Not at all concerned7.625.3
Change BL to M12 - I3: Extremely concerned-3.3-6.6
Change BL to M12 - I3: Moderately concerned-3.2-6.4
Change BL to M12 - I3: Somewhat concerned-13.2-6.3
Change BL to M12 - I3: Slightly concerned14.01.0
Change BL to M12 - I3: Not at all concerned5.618.3
Change BL to M12 - I4: Extremely concerned-1.2-6.3
Change BL to M12 - I4: Moderately concerned-1.2-16.7
Change BL to M12 - I4: Somewhat concerned-11.43.9
Change BL to M12 - I4: Slightly concerned10.317.7
Change BL to M12 - I4: Not at all concerned3.61.4
Change BL to M12 - I5: Extremely concerned-7.0-6.6
Change BL to M12 - I5: Moderately concerned-1.4-3.0
Change BL to M12 - I5: Somewhat concerned-0.4-6.4
Change BL to M12 - I5: Slightly concerned1.24.0
Change BL to M12 - I5: Not at all concerned7.612.0
SecondaryMean AIM Score Assessed for PSPs

The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 6 and Month 12
Reported as:
Mean · Scores on a scale
Mean AIM Score Assessed for PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Baseline4.46 ± 0.694.41 ± 0.68
Month 64.57 ± 0.644.57 ± 0.55
Month 124.61 ± 0.634.60 ± 0.67
SecondaryNumber of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Very helpful3532
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Helpful2723
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Somewhat helpful1210
Getting Started Brochure that gives an overview of how to get started with APRETUDE — A little helpful72
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Not at all helpful12
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Did not use it236
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Missing129
Patient Brochure that helps understand the process of receiving APRETUDE injections — Very helpful3730
Patient Brochure that helps understand the process of receiving APRETUDE injections — Helpful2725
Patient Brochure that helps understand the process of receiving APRETUDE injections — Somewhat helpful1110
Patient Brochure that helps understand the process of receiving APRETUDE injections — A little helpful53
Patient Brochure that helps understand the process of receiving APRETUDE injections — Not at all helpful10
Patient Brochure that helps understand the process of receiving APRETUDE injections — Did not use it247
Patient Brochure that helps understand the process of receiving APRETUDE injections — Missing129
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Very helpful320
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Helpful250
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Somewhat helpful80
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — A little helpful70
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Not at all helpful10
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Did not use it320
Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Missing120
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Very helpful300
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Helpful220
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Somewhat helpful80
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — A little helpful60
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Not at all helpful10
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Did not use it380
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Missing120
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Very helpful300
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Helpful250
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Somewhat helpful70
The What to Expect video which shows what to expect during the APRETUDE process (DI) — A little helpful50
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Not at all helpful00
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Did not use it380
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Missing120
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Very helpful260
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Helpful230
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Somewhat helpful90
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — A little helpful60
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Not at all helpful00
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Did not use it410
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Missing120
The study website to access APRETDUE information (RI) — Very helpful028
The study website to access APRETDUE information (RI) — Helpful019
The study website to access APRETDUE information (RI) — Somewhat helpful013
The study website to access APRETDUE information (RI) — A little helpful04
The study website to access APRETDUE information (RI) — Not at all helpful00
The study website to access APRETDUE information (RI) — Did not use it011
The study website to access APRETDUE information (RI) — Missing09
The study app to access APRETUDE information (DI) — Very helpful230
The study app to access APRETUDE information (DI) — Helpful220
The study app to access APRETUDE information (DI) — Somewhat helpful120
The study app to access APRETUDE information (DI) — A little helpful60
The study app to access APRETUDE information (DI) — Not at all helpful00
The study app to access APRETUDE information (DI) — Did not use it420
The study app to access APRETUDE information (DI) — Missing120
SecondaryNumber of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI).

Time frame:
At Month 6
Reported as:
Count of participants · Participants
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Very helpful2824
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Helpful1717
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Somewhat helpful186
Getting Started Brochure that gives an overview of how to get started with APRETUDE — A little helpful30
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Not at all helpful10
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Did not receive/Did not use it2516
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Missing2521
Patient Brochure helps understand the process of receiving APRETUDE injections — Very helpful2921
Patient Brochure helps understand the process of receiving APRETUDE injections — Helpful1718
Patient Brochure helps understand the process of receiving APRETUDE injections — Somewhat helpful147
Patient Brochure helps understand the process of receiving APRETUDE injections — A little helpful21
Patient Brochure helps understand the process of receiving APRETUDE injections — Not at all helpful10
Patient Brochure helps understand the process of receiving APRETUDE injections — Did not receive/Did not use it2916
Patient Brochure helps understand the process of receiving APRETUDE injections — Missing2521
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Very helpful270
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Helpful190
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Somewhat helpful80
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — A little helpful50
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Not at all helpful10
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Did not receive/Did not use it320
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Missing250
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Very helpful230
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Helpful200
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Somewhat helpful80
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — A little helpful50
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Not at all helpful20
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Did not receive/Did not use it340
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Missing250
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Very helpful260
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Helpful160
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Somewhat helpful90
The What to Expect video which shows what to expect during the APRETUDE process (DI) — A little helpful40
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Not at all helpful10
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Did not receive/Did not use it360
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Missing250
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Very helpful220
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Helpful150
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Somewhat helpful100
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — A little helpful60
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Not at all helpful10
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Did not receive/Did not use it380
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Missing250
The study website to access APRETDUE information (RI) — Very helpful021
The study website to access APRETDUE information (RI) — Helpful016
The study website to access APRETDUE information (RI) — Somewhat helpful08
The study website to access APRETDUE information (RI) — A little helpful02
The study website to access APRETDUE information (RI) — Not at all helpful01
The study website to access APRETDUE information (RI) — Did not receive/Did not use it015
The study website to access APRETDUE information (RI) — Missing021
The study app to access APRETUDE information (DI) — Very helpful240
The study app to access APRETUDE information (DI) — Helpful170
The study app to access APRETUDE information (DI) — Somewhat helpful150
The study app to access APRETUDE information (DI) — A little helpful80
The study app to access APRETUDE information (DI) — Not at all helpful50
The study app to access APRETUDE information (DI) — Did not receive/Did not use it230
The study app to access APRETUDE information (DI) — Missing250
Important safety information document details safety information relating to APRETUDE — Very helpful2619
Important safety information document details safety information relating to APRETUDE — Helpful1718
Important safety information document details safety information relating to APRETUDE — Somewhat helpful119
Important safety information document details safety information relating to APRETUDE — A little helpful80
Important safety information document details safety information relating to APRETUDE — Not at all helpful21
Important safety information document details safety information relating to APRETUDE — Did not receive/Did not use it2816
Important safety information document details safety information relating to APRETUDE — Missing2521
Important facts document details important facts relating to APRETUDE — Very helpful2619
Important facts document details important facts relating to APRETUDE — Helpful1917
Important facts document details important facts relating to APRETUDE — Somewhat helpful109
Important facts document details important facts relating to APRETUDE — A little helpful41
Important facts document details important facts relating to APRETUDE — Not at all helpful11
Important facts document details important facts relating to APRETUDE — Did not receive/Did not use it3216
Important facts document details important facts relating to APRETUDE — Missing2521
A flyer on PrEP options (DI) — Very helpful220
A flyer on PrEP options (DI) — Helpful160
A flyer on PrEP options (DI) — Somewhat helpful90
A flyer on PrEP options (DI) — A little helpful20
A flyer on PrEP options (DI) — Not at all helpful20
A flyer on PrEP options (DI) — Did not receive/Did not use it410
A flyer on PrEP options (DI) — Missing250
SecondaryNumber of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Very helpful2324
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Helpful2614
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Somewhat helpful58
Getting Started Brochure that gives an overview of how to get started with APRETUDE — A little helpful52
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Not at all helpful02
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Did not receive/Did not use it1813
Getting Started Brochure that gives an overview of how to get started with APRETUDE — Missing4021
Patient Brochure helps understand the process of receiving APRETUDE injections — Very helpful2222
Patient Brochure helps understand the process of receiving APRETUDE injections — Helpful2714
Patient Brochure helps understand the process of receiving APRETUDE injections — Somewhat helpful610
Patient Brochure helps understand the process of receiving APRETUDE injections — A little helpful43
Patient Brochure helps understand the process of receiving APRETUDE injections — Not at all helpful01
Patient Brochure helps understand the process of receiving APRETUDE injections — Did not receive/Did not use it1813
Patient Brochure helps understand the process of receiving APRETUDE injections — Missing4021
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Very helpful250
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Helpful200
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Somewhat helpful60
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — A little helpful50
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Not at all helpful00
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Did not receive/Did not use it210
Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Missing400
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Very helpful250
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Helpful180
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Somewhat helpful70
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — A little helpful30
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Not at all helpful00
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Did not receive/Did not use it240
The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Missing400
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Very helpful260
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Helpful170
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Somewhat helpful60
The What to Expect video which shows what to expect during the APRETUDE process (DI) — A little helpful50
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Not at all helpful00
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Did not receive/Did not use it230
The What to Expect video which shows what to expect during the APRETUDE process (DI) — Missing400
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Very helpful220
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Helpful200
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Somewhat helpful80
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — A little helpful30
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Not at all helpful00
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Did not receive/Did not use it240
The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Missing400
The study website to access APRETDUE information (RI) — Very helpful019
The study website to access APRETDUE information (RI) — Helpful016
The study website to access APRETDUE information (RI) — Somewhat helpful07
The study website to access APRETDUE information (RI) — A little helpful07
The study website to access APRETDUE information (RI) — Not at all helpful01
The study website to access APRETDUE information (RI) — Did not receive/Did not use it013
The study website to access APRETDUE information (RI) — Missing021
The study app/website to access APRETUDE information - the Pillar Spot (DI) — Very helpful220
The study app/website to access APRETUDE information - the Pillar Spot (DI) — Helpful190
The study app/website to access APRETUDE information - the Pillar Spot (DI) — Somewhat helpful90
The study app/website to access APRETUDE information - the Pillar Spot (DI) — A little helpful80
The study app/website to access APRETUDE information - the Pillar Spot (DI) — Not at all helpful10
The study app/website to access APRETUDE information - the Pillar Spot (DI) — Did not receive/Did not use it180
The study app/website to access APRETUDE information - the Pillar Spot (DI) — Missing400
Important safety information document details safety information relating to APRETUDE — Very helpful2219
Important safety information document details safety information relating to APRETUDE — Helpful2217
Important safety information document details safety information relating to APRETUDE — Somewhat helpful99
Important safety information document details safety information relating to APRETUDE — A little helpful25
Important safety information document details safety information relating to APRETUDE — Not at all helpful01
Important safety information document details safety information relating to APRETUDE — Did not receive/Did not use it2212
Important safety information document details safety information relating to APRETUDE — Missing4021
Important facts document details important facts relating to APRETUDE — Very helpful2120
Important facts document details important facts relating to APRETUDE — Helpful2316
Important facts document details important facts relating to APRETUDE — Somewhat helpful87
Important facts document details important facts relating to APRETUDE — A little helpful16
Important facts document details important facts relating to APRETUDE — Not at all helpful01
Important facts document details important facts relating to APRETUDE — Did not receive/Did not use it2413
Important facts document details important facts relating to APRETUDE — Missing4021
A flyer on PrEP options — Very helpful2219
A flyer on PrEP options — Helpful1714
A flyer on PrEP options — Somewhat helpful87
A flyer on PrEP options — A little helpful25
A flyer on PrEP options — Not at all helpful11
A flyer on PrEP options — Did not receive/Did not use it2717
A flyer on PrEP options — Missing4021
SecondaryChange From Baseline in Mean AIM Score in PSPs

This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.

Time frame:
At Month 6 and Month 12 compared to baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in Mean AIM Score in PSPs
Scores on a scaleDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Month 6 compared to BL0.17 ± 0.660.20 ± 0.72
Month 12 compared to BL0.27 ± 0.630.19 ± 0.87
SecondaryPercentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy

In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV \& PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.

Time frame:
At Month 6 and Month 12 compared to Baseline (Month 1)
Reported as:
Number · Percentage of participants
Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy
Percentage of participantsDI - PSPRI - PSP
Change BL to M6 - I1: Very helpful-2.9-4.6
Change BL to M6 - I1: Helpful-7.2-3.7
Change BL to M6 - I1: Somewhat helpful8.1-3.8
Change BL to M6 - I1: A little helpful-3.4-2.7
Change BL to M6 - I1: Not at all helpful0.1-2.7
Change BL to M6 - I1: I did not use it5.317.4
Change BL to M6 - I2: Very helpful-3.7-6.7
Change BL to M6 - I2: Helpful-7.2-4.8
Change BL to M6 - I2: Somewhat helpful4.7-2.2
Change BL to M6 - I2: A little helpful-2.6-2.4
Change BL to M6 - I2: Not at all helpful0.10.0
Change BL to M6 - I2: I did not use it8.716.1
Change BL to M6 - I3: Very helpful-1.1—
Change BL to M6 - I3: Helpful-3.2—
Change BL to M6 - I3: Somewhat helpful1.1—
Change BL to M6 - I3: A little helpful-1.2—
Change BL to M6 - I3: Not at all helpful0.1—
Change BL to M6 - I3: I did not use it4.3—
Change BL to M6 - I4: Very helpful-3.6—
Change BL to M6 - I4: Helpful0.8—
Change BL to M6 - I4: Somewhat helpful1.1—
Change BL to M6 - I4: A little helpful-0.3—
Change BL to M6 - I4: Not at all helpful1.2—
Change BL to M6 - I4: I did not use it0.8—
Change BL to M6 - I5: Very helpful-0.3—
Change BL to M6 - I5: Helpful-6.4—
Change BL to M6 - I5: Somewhat helpful3.1—
Change BL to M6 - I5: A little helpful-0.4—
Change BL to M6 - I5: Not at all helpful1.1—
Change BL to M6 - I5: I did not use it2.9—
Change BL to M6 - I6: Very helpful-0.8—
Change BL to M6 - I6: Helpful-5.6—
Change BL to M6 - I6: Somewhat helpful2.3—
Change BL to M6 - I6: A little helpful0.8—
Change BL to M6 - I6: Not at all helpful1.1—
Change BL to M6 - I6: I did not use it2.3—
Change BL to M6 - I7: Very helpful—-4.0
Change BL to M6 - I7: Helpful—0.1
Change BL to M6 - I7: Somewhat helpful—-4.6
Change BL to M6 - I7: A little helpful—-2.2
Change BL to M6 - I7: Not at all helpful—1.6
Change BL to M6 - I7: I did not use it—9.1
Change BL to M6 - I8: Very helpful4.2—
Change BL to M6 - I8: Helpful-2.5—
Change BL to M6 - I8: Somewhat helpful4.9—
Change BL to M6 - I8: A little helpful3.0—
Change BL to M6 - I8: Not at all helpful5.4—
Change BL to M6 - I8: I did not use it-15.0—
Change BL to M12 - I1: Very helpful-3.5-4.6
Change BL to M12 - I1: Helpful8.1-8.4
Change BL to M12 - I1: Somewhat helpful-4.9-0.6
Change BL to M12 - I1: A little helpful-0.20.5
Change BL to M12 - I1: Not at all helpful-1.00.5
Change BL to M12 - I1: I did not use it1.512.6
Change BL to M12 - I2: Very helpful-6.7-5.1
Change BL to M12 - I2: Helpful9.4-11.1
Change BL to M12 - I2: Somewhat helpful-2.72.5
Change BL to M12 - I2: A little helpful0.40.8
Change BL to M12 - I2: Not at all helpful-1.01.6
Change BL to M12 - I2: I did not use it0.511.3
Change BL to M12 - I3: Very helpful2.0—
Change BL to M12 - I3: Helpful2.2—
Change BL to M12 - I3: Somewhat helpful0.2—
Change BL to M12 - I3: A little helpful-0.2—
Change BL to M12 - I3: Not at all helpful-1.0—
Change BL to M12 - I3: I did not use it-3.2—
Change BL to M12 - I4: Very helpful3.9—
Change BL to M12 - I4: Helpful2.4—
Change BL to M12 - I4: Somewhat helpful1.5—
Change BL to M12 - I4: A little helpful-1.8—
Change BL to M12 - I4: Not at all helpful-1.0—
Change BL to M12 - I4: I did not use it-5.0—
Change BL to M12 - I5: Very helpful5.2—
Change BL to M12 - I5: Helpful-1.7—
Change BL to M12 - I5: Somewhat helpful1.1—
Change BL to M12 - I5: A little helpful1.7—
Change BL to M12 - I5: Not at all helpful0.0—
Change BL to M12 - I5: I did not use it-6.3—
Change BL to M12 - I6: Very helpful3.8—
Change BL to M12 - I6: Helpful4.1—
Change BL to M12 - I6: Somewhat helpful1.8—
Change BL to M12 - I6: A little helpful-1.8—
Change BL to M12 - I6: Not at all helpful0.0—
Change BL to M12 - I6: I did not use it-7.9—
Change BL to M12 - I7: Very helpful—-7.2
Change BL to M12 - I7: Helpful—0.1
Change BL to M12 - I7: Somewhat helpful—-6.2
Change BL to M12 - I7: A little helpful—5.8
Change BL to M12 - I7: Not at all helpful—1.6
Change BL to M12 - I7: I did not use it—6.0
Change BL to M12 - I8: Very helpful6.7—
Change BL to M12 - I8: Helpful3.7—
Change BL to M12 - I8: Somewhat helpful0.3—
Change BL to M12 - I8: A little helpful4.7—
Change BL to M12 - I8: Not at all helpful1.3—
Change BL to M12 - I8: I did not use it-16.6—
SecondaryNumber of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use
ParticipantsDI - SSPRI - SSP
Frequently Asked Questions Brochure — Not at all useful10
Frequently Asked Questions Brochure — A little useful31
Frequently Asked Questions Brochure — Somewhat useful51
Frequently Asked Questions Brochure — Useful58
Frequently Asked Questions Brochure — Very Useful52
Readiness Consideration — Not at all useful00
Readiness Consideration — A little useful20
Readiness Consideration — Somewhat useful32
Readiness Consideration — Useful57
Readiness Consideration — Very Useful62
Get Started Overview-Init/Adm Guide — Not at all useful00
Get Started Overview-Init/Adm Guide — A little useful30
Get Started Overview-Init/Adm Guide — Somewhat useful42
Get Started Overview-Init/Adm Guide — Useful67
Get Started Overview-Init/Adm Guide — Very Useful62
Injection Education Video — Not at all useful00
Injection Education Video — A little useful00
Injection Education Video — Somewhat useful55
Injection Education Video — Useful87
Injection Education Video — Very Useful156
Provider Website- location where all materials and videos on APRETUDE are located (RI) — Not at all useful02
Provider Website- location where all materials and videos on APRETUDE are located (RI) — A little useful00
Provider Website- location where all materials and videos on APRETUDE are located (RI) — Somewhat useful02
Provider Website- location where all materials and videos on APRETUDE are located (RI) — Useful08
Provider Website- location where all materials and videos on APRETUDE are located (RI) — Very Useful01
Patient Materials — Not at all useful00
Patient Materials — A little useful30
Patient Materials — Somewhat useful32
Patient Materials — Useful710
Patient Materials — Very Useful83
Implementation Guidance Video (DI) — Not at all useful00
Implementation Guidance Video (DI) — A little useful20
Implementation Guidance Video (DI) — Somewhat useful20
Implementation Guidance Video (DI) — Useful90
Implementation Guidance Video (DI) — Very Useful40
Appointment Scheduler — Not at all useful10
Appointment Scheduler — A little useful00
Appointment Scheduler — Somewhat useful20
Appointment Scheduler — Useful65
Appointment Scheduler — Very Useful62
Pre-scheduled Appointment Guidance (DI) — Not at all useful00
Pre-scheduled Appointment Guidance (DI) — A little useful00
Pre-scheduled Appointment Guidance (DI) — Somewhat useful30
Pre-scheduled Appointment Guidance (DI) — Useful60
Pre-scheduled Appointment Guidance (DI) — Very Useful60
Designated Injection Days Guidance (DI) — Not at all useful00
Designated Injection Days Guidance (DI) — A little useful10
Designated Injection Days Guidance (DI) — Somewhat useful50
Designated Injection Days Guidance (DI) — Useful70
Designated Injection Days Guidance (DI) — Very Useful20
Drop-in Injection Visits Guidance (DI) — Not at all useful00
Drop-in Injection Visits Guidance (DI) — A little useful00
Drop-in Injection Visits Guidance (DI) — Somewhat useful40
Drop-in Injection Visits Guidance (DI) — Useful40
Drop-in Injection Visits Guidance (DI) — Very Useful40
Transport Support to Patient Appt (DI) — Not at all useful00
Transport Support to Patient Appt (DI) — A little useful00
Transport Support to Patient Appt (DI) — Somewhat useful40
Transport Support to Patient Appt (DI) — Useful50
Transport Support to Patient Appt (DI) — Very Useful110
Monthly Implement Facilitation Call (DI) — Not at all useful20
Monthly Implement Facilitation Call (DI) — A little useful00
Monthly Implement Facilitation Call (DI) — Somewhat useful50
Monthly Implement Facilitation Call (DI) — Useful90
Monthly Implement Facilitation Call (DI) — Very Useful80
Group Implement Facilitation Calls (DI) — Not at all useful10
Group Implement Facilitation Calls (DI) — A little useful10
Group Implement Facilitation Calls (DI) — Somewhat useful50
Group Implement Facilitation Calls (DI) — Useful80
Group Implement Facilitation Calls (DI) — Very Useful90
Document on How Discuss Sex Health (DI) — Not at all useful00
Document on How Discuss Sex Health (DI) — A little useful10
Document on How Discuss Sex Health (DI) — Somewhat useful30
Document on How Discuss Sex Health (DI) — Useful60
Document on How Discuss Sex Health (DI) — Very Useful40
PILLAR Spot (DI) — Not at all useful10
PILLAR Spot (DI) — A little useful30
PILLAR Spot (DI) — Somewhat useful70
PILLAR Spot (DI) — Useful130
PILLAR Spot (DI) — Very Useful100
SecondaryNumber of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Brochures and other print materials to educate you on APRETUDE — Not at all useful10
Brochures and other print materials to educate you on APRETUDE — Not very useful21
Brochures and other print materials to educate you on APRETUDE — Somewhat useful1010
Brochures and other print materials to educate you on APRETUDE — Useful2312
Brochures and other print materials to educate you on APRETUDE — Extremely useful1312
Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Not at all useful10
Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Not very useful10
Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Somewhat useful80
Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Useful210
Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Extremely useful90
A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Not at all useful20
A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Not very useful00
A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Somewhat useful30
A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Useful60
A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Extremely useful40
Reminders about injections — Not at all useful30
Reminders about injections — Not very useful20
Reminders about injections — Somewhat useful53
Reminders about injections — Useful2522
Reminders about injections — Extremely useful3026
Having video or telephone appointments with your doctor — Not at all useful10
Having video or telephone appointments with your doctor — Not very useful00
Having video or telephone appointments with your doctor — Somewhat useful31
Having video or telephone appointments with your doctor — Useful77
Having video or telephone appointments with your doctor — Extremely useful68
Sending chats or texts to your doctor on the Pillar Spot (DI) — Not at all useful10
Sending chats or texts to your doctor on the Pillar Spot (DI) — Not very useful00
Sending chats or texts to your doctor on the Pillar Spot (DI) — Somewhat useful30
Sending chats or texts to your doctor on the Pillar Spot (DI) — Useful110
Sending chats or texts to your doctor on the Pillar Spot (DI) — Extremely useful80
Having a nurse come home to conduct your HIV test (DI) — Not at all useful10
Having a nurse come home to conduct your HIV test (DI) — Not very useful00
Having a nurse come home to conduct your HIV test (DI) — Somewhat useful10
Having a nurse come home to conduct your HIV test (DI) — Useful20
Having a nurse come home to conduct your HIV test (DI) — Extremely useful10
Having a nurse come home to give your injection (DI) — Not at all useful10
Having a nurse come home to give your injection (DI) — Not very useful00
Having a nurse come home to give your injection (DI) — Somewhat useful10
Having a nurse come home to give your injection (DI) — Useful20
Having a nurse come home to give your injection (DI) — Extremely useful10
Receiving transportation to the clinic/doctor's office for your injection (DI) — Not at all useful10
Receiving transportation to the clinic/doctor's office for your injection (DI) — Not very useful00
Receiving transportation to the clinic/doctor's office for your injection (DI) — Somewhat useful20
Receiving transportation to the clinic/doctor's office for your injection (DI) — Useful40
Receiving transportation to the clinic/doctor's office for your injection (DI) — Extremely useful150
A website/app to access APRETUDE information- the Pillar Spot (DI) — Not at all useful20
A website/app to access APRETUDE information- the Pillar Spot (DI) — Not very useful10
A website/app to access APRETUDE information- the Pillar Spot (DI) — Somewhat useful80
A website/app to access APRETUDE information- the Pillar Spot (DI) — Useful140
A website/app to access APRETUDE information- the Pillar Spot (DI) — Extremely useful70
The website to access APRETUDE information (RI) — Not at all useful01
The website to access APRETUDE information (RI) — Not very useful01
The website to access APRETUDE information (RI) — Somewhat useful06
The website to access APRETUDE information (RI) — Useful011
The website to access APRETUDE information (RI) — Extremely useful06
SecondaryNumber of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI

Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI
ParticipantsDI - SSPRI - SSP
Medication Administration Planner74
Frequently Asked Questions (FAQs)118
Readiness Considerations44
Getting Started Overview411
Injection Education Video1310
Drop-in visits (DI)110
Designated injection days (DI)50
Prescheduled Appointments (DI)180
Transportation services (DI)100
PrEP Communication Options Tool (DI)80
Implementation guidance video (DI)100
How to discuss sexual health guidance (DI)30
Acquisition Tracker (DI)10
SecondaryNumber of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs)

Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs)
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Getting Started brochure109
Participant handbook710
Patient brochure712
Patient website (RI)011
What to expect video (DI)130
Myths facts video (DI)90
HIV education video (DI)110
ViiV Connect Assistance Video (DI)60
Reminder service text (DI)70
Appointment scheduler (DI)50
SecondaryNumber of Injections Occurring Within Target Window From Target Date

This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of units · Injections
Number of Injections Occurring Within Target Window From Target Date
InjectionsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Dose 210376
Dose 37757
Dose 46649
Dose 55045
Dose 64430
Dose 73527
Dose 800
SecondaryNumber of PSPs Completing Target Number of Injections

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Completing Target Number of Injections
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Number of PSPs Completing Target Number of Injections8163
SecondaryNumber of PSPs With Perceptions of Facilitators to Fidelity to Injections

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Perceptions of Facilitators to Fidelity to Injections
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
APRETUDE Fitting life2320
Clinic staff supporting incorporation of APRETUDE into schedule1510
Booking appointments in advance1311
Easy to fit into life (convenience, etc.)168
No transportation issues515
Good fit with work schedule136
Clinic hours aligned with patient schedule114
SecondaryNumber of PSPs With Perceptions of Barriers to Fidelity to Injections

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Perceptions of Barriers to Fidelity to Injections
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Discomfort1411
Clinic challenges46
Work challenges25
SecondaryNumber of SSPs With Perceptions of Facilitators to Fidelity to Injections

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Perceptions of Facilitators to Fidelity to Injections
ParticipantsDI - SSPRI - SSP
Resources: Communication (call, email and text)72
Resources: Dedicated injection nurse for follow-up23
Resources: Patient education about importance of adherence14
Resources: Dedicated support staff for each step: education, authorization, etc40
Resources: Flexibility of using oral PrEP for bridging when needed13
Support: Scheduling appointments in advance43
Support: Team dedicated for follow-up51
Patient Communication: Increasing global communication65
Patient Communication: Encouraging proactively engaging patients with scheduling63
Patient Communication: Accessibility for patients for open line communication82
Patient feasibility: APRETUDE is feasible for patients93
Patient feasibility: Clinical staff making the process run smoothly44
Patient feasibility: Working around patient schedule helps with feasibility33
SecondaryNumber of SSPs With Perceptions of Barriers to Fidelity to Injections

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Perceptions of Barriers to Fidelity to Injections
ParticipantsDI - SSPRI - SSP
Patient Barriers: Scheduling Barriers42
Patient Barriers: Vulnerable Population22
Patient Barriers: Traveling22
Patient Barriers: Patients hard to contact (e.g., no phone access)22
Staff Challenges: Concern about patients missing injection window42
Staff Challenges: Not being able to contact patients who miss an appointment13
SecondaryNumber of SSPs Who Administer Sexual Health Assessment (SHA)

In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Who Administer Sexual Health Assessment (SHA)
ParticipantsDI - SSP
Yes14
No And Not Planning to Use the Sexual Health Assessment14
No But Planning to Use the Sexual Health Assessment4
I don't know20
SecondaryNumber of Eligible PSPs for Which SHA Are Administered

In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Eligible PSPs for Which SHA Are Administered
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Yes3935
No1513
I don't know2315
Missing4021
SecondaryNumber of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12
ParticipantsMen Who Have Sex With Men (MSM)Transgender Men (TGM)
Yes731
No253
I don't know362
Missing556
SecondaryNumber of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA

In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA
ParticipantsMen Who Have Sex With Men (MSM)Transgender Men (TGM)
No51
Yes1285
I prefer not to answer10
Missing556
SecondaryNumber of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months

In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question "Have you taken oral PreP in the last 6 months" and number of PSPs who had not heard of PreP.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — Yes7061
Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — No3015
Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — I don't know/prefer not to answer73
Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — Missing105
Before enrolling in this study, had you heard of APRETUDE? — Yes6858
Before enrolling in this study, had you heard of APRETUDE? — No3921
Before enrolling in this study, had you heard of APRETUDE? — I don't know/prefer not to answer00
Before enrolling in this study, had you heard of APRETUDE? — Missing105
Have you taken oral PrEP in the last 6 months? — Yes7765
Have you taken oral PrEP in the last 6 months? — No2611
Have you taken oral PrEP in the last 6 months? — I don't know/prefer not to answer21
Have you taken oral PrEP in the last 6 months? — Missing127
SecondaryNumber of PSPs Who Initiate APRETUDE After Taking the SHA

In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP. Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Who Initiate APRETUDE After Taking the SHA
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Have you taken oral PrEP in the last 6 months? — Yes7765
Have you taken oral PrEP in the last 6 months? — No2611
Have you taken oral PrEP in the last 6 months? — I prefer not to answer21
Have you taken oral PrEP in the last 6 months? — Missing127
Have you ever taken oral PrEP — Yes51
Have you ever taken oral PrEP — No110
Have you ever taken oral PrEP — I prefer not to answer10
Have you ever taken oral PrEP — Missing1111
SecondaryNumber of PSPs With Perceptions of SHA

Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Perceptions of SHA
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
SHA was received by PSPs160
SHA was not received by PSPs30
SHA received/not received- Missing40
SHA found useful by PSPs150
SHA not found useful by PSPs00
SHA found useful/not useful- Missing10
SecondaryNumber of SSPs With Perceptions of SHA

In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Perceptions of SHA
ParticipantsDI - SSP
The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Completely disagree1
The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Disagree1
The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Neither agree nor disagree3
The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Agree8
The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Completely agree5
The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Completely disagree1
The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Disagree0
The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Neither agree nor disagree3
The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Agree10
The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Completely agree4
The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Completely disagree1
The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Disagree0
The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Neither agree nor disagree3
The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Agree8
The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Completely agree6
SecondaryNumber of Modifications Reported by SSPs Using FRAME-IS

The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Reported as:
Number · Number of Modifications
Number of Modifications Reported by SSPs Using FRAME-IS
Number of ModificationsDI- SSPRI- SSP
Trial Month 2 Modifications63
Trial Month 3 Modifications48
Trial Month 4 Modifications30
Trial Month 5 Modifications35
Trial Month 6 Modifications43
Trial Month 7 Modifications14
Trial Month 8 Modifications32
Trial Month 9 Modifications20
Trial Month 10 Modifications100
Trial Month 11 Modifications20
Trial Month 12 Modifications51
SecondaryNumber of Modifications for Each Category Reported by SSPs Using FRAME-IS

The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Number · Number of Modifications
Number of Modifications for Each Category Reported by SSPs Using FRAME-IS
Number of ModificationsDI - SSPRI - SSP
Content: Modification made to the content of APRETUDE materials and tools124
Evaluation: Modification made to the staff evaluate whether APPRETUDE is working53
Training: Modification made to the staff delivering APRETUDE are trained220
Contextual: Modification made to the overall implementation of APRETUDE injection delivered3022
SecondaryNumber of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS

The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Number · Number of Modifications
Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS
Number of ModificationsDI - SSPRI - SSP
Increase the number of patients with access to APRETUDE235
Improve feasibility of the implementation effort198
Improve fit with the clinical/practice setting1810
Increase satisfaction with the implementation effort1711
Speed up injection/implementation process1712
SecondaryNumber of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies

PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Discussed tools and resources2120
Positive feedback about tools and resources107
Only used tools/resources in the beginning of PILLAR57
Does not remember tools or resources35
Resources were helpful24
Negative feedback about tools and resources24
Did not use (pay much attention to resources)22
Recommendations to staff1614
Would not change anything43
APRETUDE education within the community13
Being culturally aware and non-judgmental22
Support APRETUDE schedule21
Discussion about post-Injection discomfort12
SecondaryNumber of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE

In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Have you ever taken oral PrEP- Yes51
Have you ever taken oral PrEP- No110
Have you ever taken oral PrEP- Prefer not to answer10
Have you ever taken oral PrEP- Missing1111
The SHA asked questions to determine if PrEP was right for me- Completely disagree21
The SHA asked questions to determine if PrEP was right for me- Disagree01
The SHA asked questions to determine if PrEP was right for me- Neither agree nor disagree57
The SHA asked questions to determine if PrEP was right for me- Agree1911
The SHA asked questions to determine if PrEP was right for me- Completely Agree1315
SecondaryNumber of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs)

Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs)
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Oral PrEP used: Challenges remembering to take pill every day1611
Oral PrEP used: Side effects of oral PrEP63
APRETUDE differences to oral PrEP: Better adherence and feeling more protected45
APRETUDE differences to oral PrEP: APRETUDE More convenient than Oral62
APRETUDE differences to oral PrEP: Less/ No side effects related to oral PrEP05
Prefer APRETUDE over Oral PrEP: More convenient148
Prefer APRETUDE over Oral PrEP: Less/No side effects15
SecondaryNumber of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
I want a prevention option that is more convenient for my life6649
I won't have to remember to take PrEP everyday6345
I do not have to worry or stress about missing a dose like oral PrEP5547
I want to try a new approach and see if it fits into my life4327
I will not have to worry about HIV every day4327
SecondaryNumber of PSPs Assessed for Perception of Facilitators

General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perception of Facilitators
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Would consider APRETUDE as a long-term treatment1917
APRETUDE as long-term treatment provides protection126
APRETUDE as long-term treatment provides peace of mind46
APRETUDE as long-term treatment has concerns about insurance coverage long-term43
APRETUDE as long-term treatment has convenience over oral PrEP51
APRETUDE as long-term treatment taken as long as necessary05
Reasons others may choose APRETUDE: Convenience and ease of use83
Reasons others may choose APRETUDE: Health and prevention45
Global judgement of recommend to others1314
Experiences of care: Discussed interactions with clinic staff2121
Experiences of care: Clinic staff were friendly and kind1719
Experiences of care: PSP was treated with respect1515
Experiences of care: Clinic staff were knowledgeable127
Experiences of care: Shared decision making109
HIV/STI testing: Testing frequency was acceptable1315
HIV/STI testing: Positive experience with scheduling HIV/ STI testing1111
Reported whether they discussed APRETUDE with family / friends2118
Has discussed APRETUDE with partner(s)119
Peers have started PrEP107
Uptake of PrEP by Friends32
SecondaryNumber of PSPs Assessed for Perception of Barriers

General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Assessed for Perception of Barriers
ParticipantsDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Would not consider APRETUDE as a long-term treatment13
Cost Challenges63
Challenges with switching insurance carriers04
SecondaryNumber of SSPs Assessed for Perception of Facilitators

General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Assessed for Perception of Facilitators
ParticipantsDI - SSPRI - SSP
Supportive leadership for implementation1111
Leadership willing to help/support68
Leadership being actively involved in the process45
APRETUDE positively accepted105
Team adaptability83
Staff being supportive of the clinic offering APRETUDE116
Aiming to improve patient's health22
SecondaryNumber of SSPs Assessed for Perception of Barriers

General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs Assessed for Perception of Barriers
ParticipantsDI - SSPRI - SSP
Staff having mixed feelings94
Initial negative response due to extra workload22

Adverse events

Collected over Serious adverse events (SAEs) were reported from signing of informed consent (a period starting up to 90 days before the first dose in Month 1) to Month 12 (study completion). Non serious Drug related AEs were reported from Month 1 (first dose) to Month 12 (study completion).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dynamic Implementation (DI) - PSP0/117 (0%)1/117 (0.9%)5/117 (4.3%)
Routine Implementation (RI) - PSP0/84 (0%)0/84 (0%)6/84 (7.1%)
Most frequent serious events
Most frequent serious events
EventDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Clavicle fractureInjury, poisoning and procedural complications1/1170/84
Rib fractureInjury, poisoning and procedural complications1/1170/84
PneumothoraxRespiratory, thoracic and mediastinal disorders1/1170/84
Most frequent other events
Most frequent other events
EventDynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSP
Injection site painGeneral disorders2/1174/84
FatigueGeneral disorders2/1172/84
Injection site reactionGeneral disorders0/1171/84
Peripheral swellingGeneral disorders0/1171/84
DiarrhoeaGastrointestinal disorders0/1171/84
Depressed moodPsychiatric disorders1/1171/84
Libido decreasedPsychiatric disorders0/1171/84
Back painMusculoskeletal and connective tissue disorders0/1171/84
PainGeneral disorders1/1170/84
NauseaGastrointestinal disorders1/1170/84

Baseline characteristics

Baseline characteristics for SSPs were not collected as it was not required as per study design.

Age, Continuous
Age, Continuous(Years)Dynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSPTotal
Mean37.6 ± 11.1637.8 ± 10.7637.7 ± 10.97
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Dynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSPTotal
Cisgender Man10782189
Transgender Man10212
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dynamic Implementation (DI) - PSPRoutine Implementation (RI) - PSPTotal
American Indian or Alaska Native101
Asian628
Black of African American192948
Multiple Races246
Other, not specified202
Unknown15217
White7247119
08

Study locations

17 sites
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    San Francisco, California 94102, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20005, United States
  • GSK Investigational Site
    Miami, Florida 33140, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Sarasota, Florida 34237, United States
  • GSK Investigational Site
    Bridgeport, Kansas 06605, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Columbia, Missouri 65212, United States
  • GSK Investigational Site
    St Louis, Missouri 63117, United States
  • GSK Investigational Site
    Rochester, New York 14607, United States
  • GSK Investigational Site
    The Bronx, New York 10467, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19123, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Harlingen, Texas 78550, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Pilgrim N, Holder H, Torres JA, Ortiz R, Valenti W, Dandachi D, Shalit P, Kingcade A, Ruane P, Mercado L, Li B, Gaudion A, Merrill D, Gibbons E, Barnes N, Stassek L, Moodley R, McKeon T, Nelson KL, Garges HP, Brown K, Czarnogorski M. Implementation Journey with CAB LA for PrEP Among Men Who Have Sex with Men and Transgender Men: Insights from the PILLAR Trial Through 12 Months. AIDS Behav. 2026 Jul 12. doi: 10.1007/s10461-026-05216-0. Online ahead of print. PubMed 42437832 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2024, 26 months.

Results were first posted in Dec 2025, 1 year 4 months after primary completion.

Of 91 phase 4 interventional studies under HIV Infections, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 16, 2022
StartActual
May 18, 2022
Primary completionActual
Aug 8, 2024
CompletionActual
Aug 8, 2024
Results first posted
Dec 15, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05374525
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
May 16, 2022
Start date
May 18, 2022
Primary completion
Aug 8, 2024
Completion
Aug 8, 2024
Results posted
Dec 15, 2025
Last update
Dec 15, 2025

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion